<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Eleven children underwent BMT for <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> or <z:hpo ids='HP_0001909'>leukemia</z:hpo>, four from HLA-identical siblings and seven from unrelated donors </plain></SENT>
<SENT sid="1" pm="."><plain>Ten of the 11 were conditioned with <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> as the majority had received prior irradiation to the chest and/or abdomen </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted </plain></SENT>
<SENT sid="3" pm="."><plain>Regimen-related toxicity was more common when compared to historical controls </plain></SENT>
<SENT sid="4" pm="."><plain>Eight patients developed <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and four of eight who survived 100 days post transplant developed extensive <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD </plain></SENT>
<SENT sid="5" pm="."><plain>Non-relapse related mortality occurred in three patients </plain></SENT>
<SENT sid="6" pm="."><plain>Five patients developed recurrent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>: one died from recurrence of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo>, three died of recurrent <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and another developed two subsequent <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> (<z:hpo ids='HP_0006771'>duodenal carcinoma</z:hpo> and anaplastic <z:hpo ids='HP_0009592'>astrocytoma</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-free survival of 24% (95% confidence interval = 5-53%) </plain></SENT>
<SENT sid="8" pm="."><plain>Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> remains the major obstacle </plain></SENT>
</text></document>